Bristol's Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex Pharma
Gilead's GS-7977 is the most advanced nuc in clinical development, with multiple phase III studies already underway. Idenix is moving its nuc IDX-184 into phase II combination studies. On Monday, Vertex announced the first erly-stage, proof-of-concept data for its nuc ALS-2200 that showed the drug's potency to be comparable to that of GS-7977.
"This is clearly a significant positive for Gilead, who sees what we previously perceived as their most significant potential competitor in the Hep C space effectively taken out of the race," writes Brean Murray Carret analyst Brian Skorney in a Thursday morning research note. "We expect increased focus on Vertex and Idenix as the only other companies with nucs in clinical development that could be entertained as a
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.
>To submit a news tip, send an email to: firstname.lastname@example.org.